Previous study reported that B-Raf protooncogene, serine/threonine kinase (BRAF), and KRAS protooncogene, GTPase (KRAS) mutations, are early molecular alterations in serrated lesions and are mutually exclusive in colorectal neoplasms [16, 17]. This evidence concerns the gene MARK2 and colorectal neoplasm.